{"url_path":"/sec/espr/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1434868/0001628280-26-032870-index.html","accession_number":"0001628280-26-032870","cik":"0001434868","ticker":"ESPR","issuer_name":"Esperion Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1434868/0001628280-26-032870-index.html","primary_entity_key":"0001434868","primary_entity_name":"Esperion Therapeutics, Inc."},"word_count":648,"has_tables":true,"body_markdown":"Item 6. Exhibits\n\nThe exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, which Exhibit Index is incorporated herein by reference.\n\nEXHIBIT INDEX\n\nIncorporated by Reference to:\n\nExhibit\nNo.DescriptionForm or\nScheduleExhibit\nNo.Filing\nDate with\nSECSEC File\nNumber\n\n[2](https://www.sec.gov/Archives/edgar/data/1434868/000162828026013552/exhibit21.htm)[.1](https://www.sec.gov/Archives/edgar/data/1434868/000162828026013552/exhibit21.htm)\n\n[Agreement and Plan of Merger, dated March 2, 2026, by and among Cirrus Transaction Subsidiary, Inc., the Registrant, Corstasis Therapeutics Inc., Shareholder Representative Services LLC, and Benjamin Esque](https://www.sec.gov/Archives/edgar/data/1434868/000162828026013552/exhibit21.htm)[.](https://www.sec.gov/Archives/edgar/data/1434868/000162828026013552/exhibit21.htm)\n8-K\n2.1\n\nMarch 3, 2026\n\n001-35986\n\n[2.2†](https://www.sec.gov/Archives/edgar/data/1434868/000110465926053482/tm2613340d1_ex2-1.htm)\n\n[Agreement and Plan of Merger, dated as of May 1, 2026, by and among Essence Parent Inc., Essence MergerCo Inc. and Esperion Therapeutics, Inc.](https://www.sec.gov/Archives/edgar/data/1434868/000110465926053482/tm2613340d1_ex2-1.htm)\n8-K2.1\nMay 1, 2026\n001-35986\n\n[3.1](https://www.sec.gov/Archives/edgar/data/1434868/000104746913006896/a2215641zex-3_2.htm)\n\n[Amended and Restated Certificate of Incorporation of the Registrant](https://www.sec.gov/Archives/edgar/data/1434868/000104746913006896/a2215641zex-3_2.htm)\n\nS-1\n3.2June 12, 2013333-188595\n\n[3.2](https://www.sec.gov/Archives/edgar/data/1434868/000162828022015488/exhibit31.htm)\n\n[Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant](https://www.sec.gov/Archives/edgar/data/1434868/000162828022015488/exhibit31.htm)\n8-K3.1May 26, 2022001-35986\n\n[3.3](https://www.sec.gov/Archives/edgar/data/1434868/000162828022025245/exhibit31certificateofvali.htm)\n\n[Certificate of Validation relating to Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant dated May 26, 2022](https://www.sec.gov/Archives/edgar/data/1434868/000162828022025245/exhibit31certificateofvali.htm)\n8-K3.1September 20, 2022001-35986\n\n[3.4](https://www.sec.gov/Archives/edgar/data/1434868/000162828023022276/exhibit3162023.htm)\n\n[Certificate of Amendment No. 2 to Amended and Restated Certificate of Incorporation of the Registrant](https://www.sec.gov/Archives/edgar/data/1434868/000162828023022276/exhibit3162023.htm)\n8-K3.1June 15, 2023001-35986\n\n[3.5](https://www.sec.gov/Archives/edgar/data/1434868/000162828021008918/ex31-secondamendedandresta.htm)\n\n[Second Amended and Restated Bylaws of the Registrant dated April 29, 2021](https://www.sec.gov/Archives/edgar/data/1434868/000162828021008918/ex31-secondamendedandresta.htm)\n10-Q3.1May 4, 2021001-35986\n\n[4.1](https://www.sec.gov/Archives/edgar/data/1434868/000104746913006896/a2215641zex-4_1.htm)\n\n[Specimen Common Stock Certificate](https://www.sec.gov/Archives/edgar/data/1434868/000104746913006896/a2215641zex-4_1.htm)\nS-14.1June 12, 2013333-188595\n\n[1](https://www.sec.gov/Archives/edgar/data/1434868/000162828026023196/esperion-amendmentno1tocre.htm)[0.1](https://www.sec.gov/Archives/edgar/data/1434868/000162828026023196/esperion-amendmentno1tocre.htm)[†](https://www.sec.gov/Archives/edgar/data/1434868/000162828026023196/esperion-amendmentno1tocre.htm)\n\n[First Amendment to Credit Agreement, dated as of April 2, 2026, by and among the Registrant, as the borrower, the lenders party thereto and GLAS USA LLC and GLAS Americans LLC collectively as the administrative agent.](https://www.sec.gov/Archives/edgar/data/1434868/000162828026023196/esperion-amendmentno1tocre.htm)\n8-K\n10.1\n\nApril 2, 2026\n001-35986\n\n[1](https://www.sec.gov/Archives/edgar/data/1434868/000162828026023196/esperion-athyriumxroyaltyp.htm)[0.2](https://www.sec.gov/Archives/edgar/data/1434868/000162828026023196/esperion-athyriumxroyaltyp.htm)[†](https://www.sec.gov/Archives/edgar/data/1434868/000162828026023196/esperion-athyriumxroyaltyp.htm)\n\n[Royalty Purchase Agreement, dated as of April 2, 2026, by and among the Registrant and Athyrium Opportunities IV Acquisition LP.+](https://www.sec.gov/Archives/edgar/data/1434868/000162828026023196/esperion-athyriumxroyaltyp.htm)\n8-K\n10.3\n\nApril 2, 2026\n001-35986\n\n[31.1*](espr-ex311x03312026.htm)\n\n[Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](espr-ex311x03312026.htm)\n\n[31.2*](espr-ex312x03312026.htm)\n\n[Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](espr-ex312x03312026.htm)\n\n[32.1](espr-ex321x03312026.htm)[+](espr-ex321x03312026.htm)\n\n[Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](espr-ex321x03312026.htm)\n\n101.SCH*Inline XBRL Taxonomy Extension Schema Document\n\n101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document\n\n44\n\n[Table of Contents](#i335a280ed9bc4d30b23b59c9b553616f_7)\n\n101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document\n\n101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document\n\n101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document\n\n104*Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.*)\n\n*Filed herewith.\n\n+    The certifications furnished in Exhibit 32.1 hereto are deemed to be furnished with this Quarterly Report on Form 10-Q and will not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.\n\n† The schedules and similar attachments to this exhibit have been omitted pursuant to Items 601(a)(5) and 601(b)(ii) of Regulation S-K. The Registrant agrees to furnish copies of any such schedules or similar attachments to the Commission upon request. In addition, certain provisions of this exhibit have been redacted because the Registrant customarily treats the redacted information as private or confidential and the omitted information is not material. The Registrant agrees to promptly provide to the Commission on a supplemental basis an unredacted copy of the exhibit.\n\n45\n\n[Table of Contents](#i335a280ed9bc4d30b23b59c9b553616f_7)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\nESPERION THERAPEUTICS, INC.\n\nMay 8, 2026By:/s/ Sheldon L. Koenig\n\nSheldon L. Koenig\n\nPresident and Chief Executive Officer\n\n(Principal Executive Officer)\n\nMay 8, 2026By:/s/ Benjamin Halladay\n\nBenjamin Halladay\n\nChief Financial Officer\n\n(Principal Financial Officer and Principal Accounting Officer)\n\n46"}